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Patients Characteristics
Age
Median (Range) 49 (18-68)
Sex
Male 20 (67%)
Female 10 (33%)
Disease Risk at HSCT
Lille
Low 6 (20%)
Intermediate 15 (50%)
High 9 (30%)
DIPPS
Low 2 (6%)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S266eS321 S285was done in all patients and 5 patients had 1-3 courses of DLI.
On follow up of the 43 patients with MC, 24 achieved com-
plete chimerism, 10 had stable mixed chimerism and 9 had
rejection (mostly level 3 MC). Two patients developed mild
graft versus host disease after DLI.
Conclusion: Occurrence of mixed chimerism is common
after allogeneic HSCT for thalassaemia after Fludarabine/
Treosulfan/Thiotepa conditioning. Rapid tapering of immu-
nosuppression and judicious use of DLI helps in reducing the
risk of secondary graft rejection. Closer monitoring of
chimerism after HSCT needs to be done when such condi-
tioning regimens are used.Intermediate-1 6 (20%)
Intermediate-2 17 (57%)
High 5 (17%)
JAK 2 Kinase
Positive 11 (37%)
Negative 11 (37%)
Unknown 8 (24)
Spleen
Enlarged 18 (60%)
Normal 4 (13%)
Removed 8 (27%)
Albumin 1
Median 3.9
Min 2.6
Max 4.9
LDH 2
Median 487
Min 126
Max 1304
ECOG
0 5
1 17
2 4
Unknown 4
1 Albumin normal value: 3.5-4.8 g/dl
2 LDH normal value: 98-192 IU/L406
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Introduction: Allogeneic stem cell transplantation (SCT) is
potentially curative for patients with Myeloﬁbrosis (MF).
However, treatment failure is common and often associated
with slow engraftment or graft failure, risk factors for which
are poorly deﬁned.
Patients: From 2000 to 2014, 30 adult patients (median
age, 49 (range 18-68) underwent SCT for primary or sec-
ondary MF at WCMC/NYP. All patients received PBSC from
matched related (MRD-14) or matched unrelated donors
(MUD-16). Most patients received ﬂudarabine and
melphalan (n¼22) conditioning. ATG or alemtuzumab were
used for patients who underwent MUD SCT. Only a mi-
nority of patients had low risk disease by DIPPS (26.7%) or
Lille (20%) risk scores. Twenty patients had splenomegaly, 6
by physical exam and 14 by imaging studies (median 24.5
Cm, range 16.2-34).
Results: After a median follow-up of 49.5 months (range 3 to
154 months), the 4-year OS and RFS are 44% (95%CI: 29%-
67%) and 37% (95%CI: 23%-61%) respectively. Neutrophil
engraftment by day 18 occurred in 63% of patients. Platelets
were engrafted by day 25 in 41% of patients. We used a Fine
and Gray’s proportional subdistribution hazard model.
Splenomegaly was associated with delayed neutrophil
engraftment (SHR¼0.42, 95% CI¼0.21, 0.83, p¼0.01), delayed
platelet engraftment (SHR¼0.18, 95%CI¼ 0.07, 0.48, p<0.001)
and non-relapse mortality (NRM) (SHR¼3.24, 95%CI¼0.94,
11.2, p¼0.06). Elevated LDH was associated with delayed
platelet engraftment (SHR¼0.39, 95% CI¼0.16, 0.94, p¼0.04)
and NRM (SHR¼2.82, 95%CI¼ 1.08, 7.35, p¼0.03). MUD
grafts were marginally associated with delayed neutrophil
engraftment (SHR¼0.55, 95% CI¼ 0.27, 1.12, p<0.10) but not
platelet engraftment or NRM.
Conclusion: Splenomegaly contributed to delayed neutro-
phil and platelet engraftment and NRM. Splenectomy should
be considered for patients with splenomegaly in need of
transplantation. Elevated LDH was associated with delayed
platelets engraftment and NRM and might indicate more
aggressive disease.407
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Objectives: To assess the effects of additional consolida-
tion therapy in acute myeloid leukemia (AML) patients
before allogeneic hematopoietic stem cell transplantation
(HSCT).
Methods: Seventy-two AML patients (range: 18-55 years)
who transplanted in CR1 after being treated with a standard
chemotherapy (7+3) regimen were randomly divided into
two groups. Thirty-six patients in group A directly under-
went transplantation and 36 in group B received chemo-
therapy regimen (5+2) prior to allogeneic HSCT. All patients
received fully HLA-matched transplants.
Results: Themedian age at transplantationwas 38.3 in group
A and 37.2 in group B. Themale to female ratio was 21:15 and
23:13 in groups A and B, respectively. The median time to
neutrophil and platelet recovery was 8 and 27 days in group
A, while it was 9 and 19 days in group B, respectively (P: 0.77,
0.01). Acute graft-versus-host disease (GvHD) was more
frequent in group A (26 vs. 23) patients(P:0.44). Chronic
